Traci McCarty | Head of Investor Relations |
Jean-Jacques Bienaime | Chairman and Chief Executive Officer |
Jeffrey Ajer | Chief Commercial Officer |
Henry Fuchs | President, Worldwide Research and Development |
Brian Mueller | Chief Financial Officer |
Greg Guyer | Chief Technical Officer, Manufacturing and Technical Operations |
Akash Tewari | Jefferies |
Salveen Richter | Goldman Sachs |
Geoffrey Meacham | BofA Securities |
Christopher Raymond | Piper Sandler |
Robyn Karnauskas | Truist Securities |
Phil Nadeau | TD Cowen |
Joseph Schwartz | Leerink Partners |
Paul Matteis | Stifel |
Gena Wang | Barclays |
Thank you for joining BioMarin Second Quarterly Results Conference Call. Hosting today's call from BioMarin is Traci McCarty, Head of Investor Relations at BioMarin. Please go ahead, Traci.
Thank you, Katie, and thank you, everyone for joining us today. To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development.